Protein functionalized tramadol-loaded PLGA nanoparticles: Preparation, optimization, stability and pharmacodynamic studies

Drug Development and Industrial Pharmacy

Volumn 39, Issue 6, 2013, Pages 854-864

  Lalani, Jigar ^a   Rathi, Mohan ^a   Lalan, Manisha ^a   Misra, Ambikanandan ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

Brain delivery; Contour plots; Factorial design; Optimization; PLGA nanoparticles

Indexed keywords

ACETONE; LACTOFERRIN; NANOPARTICLE; POLY (DEXTRO,LEVO LACTIDE CO GLYCOLIDE ACID) NANOPARTICLE; POLYMER; POLYVINYL ALCOHOL; TRAMADOL; TRANSFERRIN; TREHALOSE; UNCLASSIFIED DRUG; WATER;

ANTINOCICEPTION; ARTICLE; COMPARATIVE STUDY; DRUG CONJUGATION; DRUG FORMULATION; DRUG STABILITY; DRUG SYNTHESIS; FREEZE DRYING; NONHUMAN; PARTICLE SIZE; RAT;

ANALGESICS, OPIOID; ANIMALS; DRUG CARRIERS; DRUG STABILITY; LACTIC ACID; NANOPARTICLES; PAIN MEASUREMENT; PARTICLE SIZE; POLYGLYCOLIC ACID; PROTEINS; RATS; RATS, WISTAR; TRAMADOL;

EID: 84877067774     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.684390     Document Type: Article

References (52)

1. Shive MS, Anderson JM. (1997). Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev, 28: 5-24.
2. Jain RA. (2000). The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials, 21:2475-2490.
3. Bala I, Hariharan S, Kumar MN. (2004). PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst, 21:387-422.
4. Nahata T, Saini TR. (2008). D-optimal designing and optimization of long acting microsphere-based injectable formulation of aripiprazole. Drug Dev Ind Pharm, 34:668-675.
5. Yoncheva K, Lambov N, Miloshev S. (2009). Modification of biodegradable poly(malate) and poly(lactic-co-glycolic acid) microparticles with low molecular polyethylene glycol. Drug Dev Ind Pharm, 35:449-454.
6. Kollipara S, Bende G, Movva S, Saha R. (2010). Application of rotatable central composite design in the preparation and optimization of poly(lactic-co-glycolic acid) nanoparticles for controlled delivery of paclitaxel. Drug Dev Ind Pharm, 36:1377-1387.
7. Shi K, Cui F, Yamamoto H, Kawashima Y. (2009). Optimized formulation of high-payload PLGA nanoparticles containing insulin-lauryl sulfate complex. Drug Dev Ind Pharm, 35:177-184.
8. Niu X, Zou W, Liu C, Zhang N, Fu C. (2009). Modified nanoprecipitation method to fabricate DNA-loaded PLGA nanoparticles. Drug Dev Ind Pharm, 35:1375-1383.
9. Quintanar-Guerrero D, Allemann E, Fessi H, Doelker E. (1998). Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind Pharm, 24:1113-1128.
10. Chen J, Li S, Shen Q, He H, Zhang Y. (2011). Enhanced cellular uptake of folic acid-conjugated PLGA-PEG nanoparticles loaded with vincristine sulfate in human breast cancer. Drug Dev Ind Pharm, 37:1339-1346.
11. Wang Y, Jiang G, Qiu T, Ding F. (2012). Preparation and evaluation of paclitaxel-loaded nanoparticle incorporated with galactose-carrying polymer for hepatocyte targeted delivery. Drug Dev Ind Pharm, 38:1039-1046.
12. Allen TM. (2002). Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer, 2:750-763.
13. Visser CC, Stevanovic S, Heleen Voorwinden L, Gaillard PJ, Crommelin DJ, Danhof M et al. (2004). Validation of the transferrin receptor for drug targeting to brain capillary endothelial cells in vitro. J Drug Target, 12:145-150.
14. Ulbrich K, Hekmatara T, Herbert E, Kreuter J. (2009). Transferrinand transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm, 71:251-256.
15. Hu K, Li J, Shen Y, Lu W, Gao X, Zhang Q et al. (2009). Lactoferrinconjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J Control Release, 134:55-61.
16. Huang R, Ke W, Han L, Liu Y, Shao K, Jiang C et al. (2010). Lactoferrin-modified nanoparticles could mediate efficient gene delivery to the brain in vivo. Brain Res Bull, 81:600-604.
17. Bamigbade TA, Langford RM. (1998). Tramadol hydrochloride: an overview of current use. Hosp Med, 59:373-376.
18. Cochran WG, Cox GM. (1957). Experimental Designs. 2nd edition. New York: Wiley.
19. Seth AK, Misra A. (2002). Mathematical modelling of preparation of acyclovir liposomes: reverse phase evaporation method. J Pharm Pharm Sci, 5:285-291.
20. El Assassy AE, Amin MM, Abdelbary AA. (2012). Immediate release three-layered chewing gum tablets of fenoprofen calcium: preparation, optimization and bioavailability studies in healthy human volunteers. Drug Dev Ind Pharm, 38:603-615.
21. Ss K, Jk B, Cc G, Ym C, Nn I, Vk M. (2013). Modulated release of 5-fluorouracil from pH-sensitive and colon targeted pellets: an industrially feasible approach. Drug Dev Ind Pharm, 39:138-145.
22. Derakhshandeh K, Erfan M, Dadashzadeh S. (2007). Encapsulation of 9-nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: factorial design, characterization and release kinetics. Eur J Pharm Biopharm, 66:34-41.
23. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. (1989). Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm, 55:R1-R4.
24. Huang YB, Tsai YH, Lee SH, Chang JS, Wu PC. (2005). Optimization of pH-independent release of nicardipine hydrochloride extendedrelease matrix tablets using response surface methodology. Int J Pharm, 289:87-95.
25. Adinarayana K, Ellaiah P. (2002). Response surface optimization of the critical medium components for the production of alkaline protease by a newly isolated Bacillus sp. J Pharm Pharm Sci, 5:272-278.
26. Akhnazarova S, Kafarov V. (1982). Experiment Optimization in Chemistry and Chemical Engineering. Moscow: Mir.
27. Derringer G, Suich R. (1980). Simultaneous-optimization of several response variables. J Qual Technol, 12:214-219.
28. Giry K, Viana M, Genty M, Wuthrich P, Chulia D. (2010). Surface responses and desirability functions to determine optimal granulation domains. Drug Dev Ind Pharm, 36:1016-1026.
29. Gupta S, Agarwal A, Gupta NK, Saraogi G, Agrawal H, Agrawal GP. (2012). Galactose decorated PLGA nanoparticles for hepatic delivery of acyclovir. Drug Dev Ind Pharm, 0(0):1-8.
30. Joshi D, Lan-Chun-Fung Y, Pritchard J. (1979). Determination of poly (vinyl alcohol) via its complex with boric acid and iodine. Anal Chim Acta, 104:153-160.
31. Sahoo SK, Labhasetwar V. (2005). Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm, 2:373-383.
32. Olivier JC, Huertas R, Lee HJ, Calon F, Pardridge WM. (2002). Synthesis of pegylated immunonanoparticles. Pharm Res, 19:1137-1143.
33. Q1A(R2). (2003). Stability testing of new drug substances and products.
34. Zimmermann M. (1983). Ethical guidelines for investigations of experimental pain in conscious animals. Pain, 16:109-110.
35. Woolfe G, MacDonald A. (1944). The evaluation of the analgesic action of pethidine hydrochloride (Demerol). J Pharmacol Exp Ther, 80:300.
36. Armstrong NA. (2006). Pharmaceutical Experimental Design and Interpretation. 2nd edition. Boca Raton, FL: CRC/Taylor & Francis.
37. Moghimi SM, Hedeman H, Muir IS, Illum L, Davis SS. (1993). An investigation of the filtration capacity and the fate of large filtered sterically-stabilized microspheres in rat spleen. Biochim Biophys Acta, 1157:233-240.
38. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. (2002). Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release, 82:105-114.
39. Song X, Zhao Y, Hou S, Xu F, Zhao R, He J et al. (2008). Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency. Eur J Pharm Biopharm, 69:445-453.
40. Song X, Zhao Y, Wu W, Bi Y, Cai Z, Chen Q et al. (2008). PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: systematic study of particle size and drug entrapment efficiency. Int J Pharm, 350:320-329.
41. Galindo-Rodriguez S, Allemann E, Fessi H, Doelker E. (2004). Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion, and nanoprecipitation methods. Pharm Res, 21:1428-1439.
42. Budhian A, Siegel SJ, Winey KI. (2005). Production of haloperidolloaded PLGA nanoparticles for extended controlled drug release of haloperidol. J Microencapsul, 22:773-785.
43. Chacon M, Molpeceres J, Berges L, Guzman M, Aberturas MR. (1999). Stability and freeze-drying of cyclosporine loaded poly (D,L-lactide-glycolide) carriers. Eur J Pharm Sci, 8:99-107.
44. Franks F. (1998). Freeze-drying of bioproducts: putting principles into practice. Eur J Pharm Biopharm, 45:221-229.
45. Sameti M, Bohr G, Ravi Kumar MN, Kneuer C, Bakowsky U, Nacken M et al. (2003). Stabilisation by freeze-drying of cationically modified silica nanoparticles for gene delivery. Int J Pharm, 266:51-60.
46. Konan YN, Gurny R, Allemann E. (2002). Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles. Int J Pharm, 233:239-252.
47. De Jaeghere F, Allemann E, Leroux JC, Stevels W, Feijen J, Doelker E et al. (1999). Formulation and lyoprotection of poly(lactic acidco- ethylene oxide) nanoparticles: influence on physical stability and in vitro cell uptake. Pharm Res, 16:859-866.
48. Chorny M, Fishbein I, Danenberg HD, Golomb G. (2002). Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics. J Control Release, 83:389-400.
49. Betancourt T, Brown B, Brannon-Peppas L. (2007). Doxorubicinloaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomedicine (Lond), 2:219-232.
50. Talukder MJ, Takeuchi T, Harada E. (2003). Receptor-mediated transport of lactoferrin into the cerebrospinal fluid via plasma in young calves. J Vet Med Sci, 65:957-964.
51. Huang RQ, Ke WL, Qu YH, Zhu JH, Pei YY, Jiang C. (2007). Characterization of lactoferrin receptor in brain endothelial capillary cells and mouse brain. J Biomed Sci, 14:121-128.
52. Fillebeen C, Descamps L, Dehouck MP, Fenart L, Benaissa M, Spik G et al. (1999). Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier. J Biol Chem, 274:7011-7017.